OS Fund

High-Level Overview

OS Fund is an American venture capital firm that invests primarily in early-stage science and technology companies focused on breakthrough discoveries in genomics, synthetic biology, computationally derived therapeutics, advanced materials, and diagnostics. Its mission centers on supporting entrepreneurs who are developing foundational platform technologies with the potential to transform industries and improve humanity’s future. The fund emphasizes computationally driven companies leveraging artificial intelligence and machine learning to accelerate innovation. OS Fund has significantly impacted the startup ecosystem by filling a gap left by traditional venture capital firms reluctant to invest in deep science ventures, thereby fostering growth in emerging scientific fields[1][2][5].

Origin Story

OS Fund was founded in 2014 by Bryan Johnson, who committed $100 million from the proceeds of selling his previous company, Braintree, to PayPal. Johnson co-leads the fund with Jeff Klunzinger. The fund was created in response to a decline in federal research and development funding and a lack of venture capital interest in science-heavy startups. The name "OS Fund" derives from "operating system," symbolizing the fund’s focus on foundational technologies that serve as platforms for further innovation. Since its inception, OS Fund has evolved to become a key player in financing early-stage companies that blend biology, computation, and materials science[1][2][4].

Core Differentiators

• Unique Investment Model: OS Fund targets early-stage companies at the intersection of science and technology, especially those using AI and machine learning to develop platform technologies.
• Network Strength: The fund leverages a network of scientific experts and entrepreneurs to support portfolio companies beyond capital, including IP strategy and scientific guidance.
• Track Record: With approximately 26 portfolio companies and around 18 exits, OS Fund has demonstrated success in nurturing deep tech ventures.
• Operating Support: OS Fund provides hands-on support post-investment, helping startups navigate complex scientific and regulatory challenges.
• Public Methodology: OS Fund has openly shared its investment evaluation methodology, particularly in synthetic biology, to encourage broader investment in emerging sciences[1][3][5].

Role in the Broader Tech Landscape

OS Fund rides the wave of convergence between biology, computation, and materials science, a trend accelerating due to advances in AI and machine learning. The timing is critical as traditional funding sources retreat from high-risk, long-horizon science ventures, creating a vacuum OS Fund fills. Market forces such as growing demand for precision medicine, sustainable materials, and computational drug discovery favor OS Fund’s portfolio focus. By backing platform technologies, OS Fund influences the broader ecosystem by enabling startups that can spawn entire new industries and scientific paradigms[1][2][4].

Quick Take & Future Outlook

Looking ahead, OS Fund is poised to continue expanding its influence by raising additional capital (noted plans to raise $250 million) to support entrepreneurs tackling global challenges through deep tech innovation. Trends such as AI-driven drug discovery, synthetic biology for sustainable manufacturing, and advanced materials development will shape its investment journey. As these fields mature, OS Fund’s role as an early backer of foundational technologies will likely enhance its reputation and impact, potentially catalyzing a new era of science-driven entrepreneurship that extends well beyond current lifetimes[2][5]. This aligns with the fund’s ethos of partnering with founders who envision transformative futures.